A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders.

ABSTRACT:

Objective

There has been no direct comparison of aripiprazole and blonanserin for schizophrenia treatment. We conducted a 24-week, rater-masked, randomized trial of aripiprazole (6-30 mg/d) vs blonanserin (4-24 mg/d) in schizophrenia patients who were not taking any antipsychotic medication for more than 2 weeks before enrollment (UMIN000011194).

Methods

The primary outcome measure for efficacy was improvement of Positive and Negative Syndrome Scale (PANSS) total score at week 24. Secondary outcomes were PANSS subscale scores, 21-item Hamilton Rating Scale for Depression (HAMD-21) score, response rate, discontinuation rate, and individual adverse events.

Results

Forty-four patients were recruited. The discontinuation rate was 86.4% in the aripiprazole group and 68.2%

SUBMITTER: Kishi T 

PROVIDER: S-EPMC5135406 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature